GB0922085D0 - Cancer diagnosis and treatment - Google Patents

Cancer diagnosis and treatment

Info

Publication number
GB0922085D0
GB0922085D0 GBGB0922085.6A GB0922085A GB0922085D0 GB 0922085 D0 GB0922085 D0 GB 0922085D0 GB 0922085 A GB0922085 A GB 0922085A GB 0922085 D0 GB0922085 D0 GB 0922085D0
Authority
GB
United Kingdom
Prior art keywords
treatment
cancer diagnosis
diagnosis
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0922085.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Priority to GBGB0922085.6A priority Critical patent/GB0922085D0/en
Publication of GB0922085D0 publication Critical patent/GB0922085D0/en
Priority to PCT/GB2010/002294 priority patent/WO2011073629A2/en
Priority to EP10803264A priority patent/EP2512601A2/en
Priority to US13/516,749 priority patent/US20120304318A1/en
Priority to JP2012543894A priority patent/JP2013514074A/ja
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0922085.6A 2009-12-17 2009-12-17 Cancer diagnosis and treatment Ceased GB0922085D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB0922085.6A GB0922085D0 (en) 2009-12-17 2009-12-17 Cancer diagnosis and treatment
PCT/GB2010/002294 WO2011073629A2 (en) 2009-12-17 2010-12-17 Cancer diagnosis and treatment
EP10803264A EP2512601A2 (en) 2009-12-17 2010-12-17 Cancer diagnosis and treatment
US13/516,749 US20120304318A1 (en) 2009-12-17 2010-12-17 Cancer diagnosis and treatment
JP2012543894A JP2013514074A (ja) 2009-12-17 2010-12-17 癌の診断および処置

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0922085.6A GB0922085D0 (en) 2009-12-17 2009-12-17 Cancer diagnosis and treatment

Publications (1)

Publication Number Publication Date
GB0922085D0 true GB0922085D0 (en) 2010-02-03

Family

ID=41717134

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0922085.6A Ceased GB0922085D0 (en) 2009-12-17 2009-12-17 Cancer diagnosis and treatment

Country Status (5)

Country Link
US (1) US20120304318A1 (enExample)
EP (1) EP2512601A2 (enExample)
JP (1) JP2013514074A (enExample)
GB (1) GB0922085D0 (enExample)
WO (1) WO2011073629A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
CA2725978A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
EP2791359B1 (en) 2011-12-13 2020-01-15 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
KR101445560B1 (ko) 2012-05-10 2014-09-29 한국수력원자력 주식회사 저준위 전리방사선에 민감한 유전자 검출 방법 및 상기 방법으로 검출된 유전자
KR101416147B1 (ko) * 2012-07-18 2014-07-09 국립암센터 위암 진단 및 치료를 위한 ａｄｃｙ3의 용도
ES3015226T3 (en) 2012-08-16 2025-04-30 Veracyte Sd Inc Prostate cancer prognosis using biomarkers
WO2014159443A1 (en) * 2013-03-14 2014-10-02 Genomedx Biosciences, Inc. Cancer biomarkers and classifiers and uses thereof
KR102384848B1 (ko) 2016-08-05 2022-04-08 더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕 방광암용 바이오마커로서의 케라틴 17
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
WO2018132916A1 (en) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
AU2018230784A1 (en) 2017-03-09 2019-10-10 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
WO2018205035A1 (en) 2017-05-12 2018-11-15 Genomedx Biosciences, Inc Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY
JP2021128140A (ja) * 2020-06-30 2021-09-02 株式会社ヤマト 漏水監視システム
CN113957152A (zh) * 2021-12-14 2022-01-21 浙江大学 一种snhg6基因的检测试剂盒及其应用
CN114592007B (zh) * 2022-04-29 2023-10-27 昆明理工大学 Far1基因的新用途
GB202415229D0 (en) * 2024-10-16 2024-11-27 Ucl Business Ltd Novel therapy

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
EP0430881A3 (en) 1989-11-29 1991-10-23 Ciba-Geigy Ag Photochromic compounds, process for their preparation and their use
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
JP2775346B2 (ja) 1992-04-03 1998-07-16 アプライド バイオシステムズ，インコーポレイテッド プローブ構成物および方法
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
EP0702720A4 (en) 1993-03-15 1997-07-02 Cell Genesys Inc METHOD OF ACCURATELY DEFINABLE DELETIONS IN DNA
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5470710A (en) 1993-10-22 1995-11-28 University Of Utah Automated hybridization/imaging device for fluorescent multiplex DNA sequencing
GB9401833D0 (en) 1994-02-01 1994-03-30 Isis Innovation Method for discovering ligands
US5552277A (en) 1994-07-19 1996-09-03 The Johns Hopkins University School Of Medicine Genetic diagnosis of prostate cancer
WO1997027317A1 (en) 1996-01-23 1997-07-31 Affymetrix, Inc. Nucleic acid analysis techniques
GB9507238D0 (en) 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
US5661028A (en) 1995-09-29 1997-08-26 Lockheed Martin Energy Systems, Inc. Large scale DNA microsequencing device
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU9484398A (en) * 1997-09-17 1999-04-05 Genentech Inc. Promotion or inhibition of angiogenesis and cardiovascularization
MXPA01002546A (es) * 1998-09-14 2004-06-11 Genentech Inc Promocion o inibhicion de angiogenesis y cardiovascularizacion.
WO2004009033A2 (en) * 2002-07-24 2004-01-29 Schering Corporation Methods of modulating proliferative conditions
GB0224436D0 (en) 2002-10-21 2002-11-27 Univ Cambridge Tech Polypetides methods and means
WO2004108896A2 (en) 2003-06-03 2004-12-16 The Board Of Trustees Of The University Of Arkansas Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
DE102004042822A1 (de) * 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
US7998695B2 (en) * 2005-02-10 2011-08-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
AU2006259583A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007006408A2 (en) * 2005-07-08 2007-01-18 Bayer Healthcare Ag Methods and kits for predicting and monitoring direct response to cancer therapy
CN101426536A (zh) * 2006-01-20 2009-05-06 妇女儿童健康研究院公司 治疗、预防和诊断骨病变的方法
EP2180320A1 (en) 2006-06-05 2010-04-28 Shimadzu Corporation Tumor marker and method for determination of the occurence of cancerous disease
AT504702A1 (de) 2006-12-22 2008-07-15 Arc Austrian Res Centers Gmbh Set von tumormarkern
EP1961825A1 (en) 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients
US7759542B2 (en) * 2007-08-01 2010-07-20 National Yang-Ming University Glycine N-methyltransferase (GNMT) animal model and use thereof

Also Published As

Publication number Publication date
US20120304318A1 (en) 2012-11-29
EP2512601A2 (en) 2012-10-24
JP2013514074A (ja) 2013-04-25
WO2011073629A3 (en) 2011-08-11
WO2011073629A2 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
EP2412297A4 (en) ENDOSCOPE OF A TYPE OF CASE FOR TREATMENT, AND ENDOSCOPE CASE
IL218575A0 (en) Treatment of cancer
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
IL215802A0 (en) Diagnostic devices and related methods
EP2412328A4 (en) MEDICAL TREATMENT DEVICE
GB0916666D0 (en) Photodynamic therapy device
IL221035A0 (en) Cancer diagnosis and imaging
IL214133A0 (en) Skin treatment
IL222958A0 (en) Cancer treatment
GB0918392D0 (en) Diagnostic and therapeutic methods
GB2465907B (en) VHZ for diagnosis and treatment of cancer
GB0900599D0 (en) Treatment
PT2630475T (pt) Método de diagnóstico e tratamento
GB201013898D0 (en) Well treatment
GB0901837D0 (en) Cancer diagnosis and treatment
ZA201203286B (en) Therapeutic and diagnostic applications against trypanosomosis
GB0916686D0 (en) Treatment of cancer
GB0913968D0 (en) Treatment
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
GB201001521D0 (en) Treatment
GB0809046D0 (en) Cancer treatment
GB0907098D0 (en) Cancer treatment and diagnosis
GB0813352D0 (en) Cancer treatment and test
GB201017857D0 (en) Methods for diagnosis and methods of treatment
GB0915801D0 (en) Theraputic treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)